Pay in 4 interest-free payments of $7.17 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Kailera IPO'd in 2025 with HRS9531 (dual GLP-1/GIP, Phase 3 China readout ~17.7% weight loss February 2026) as its lead asset and HRS-4729 (the triple agonist) as an earlier-stage follow-on
While it's essential to recognize that the FDA does not endorse off-label use, the demand for Ozempics weight loss magic couldn't be ignored, leading to practitioners across the country taking the obesity fight into their own handsor prescription pads
Adjustments are made when needed, not as a reaction to impatience but as part of a thoughtful, long-term strategy aimed at achieving meaningful and lasting success
When weight loss flattened out around week 40-44, participants did not start regaining
Nonetheless, clinicians should remain vigilant for unexplained BP rises
Thigh The front of the thigh is another recommended site for semaglutide injections
